Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy

Jesus Dominguez, Pengfei Wu, C. Subah Packer, Constance Temm, Katherine Kelly

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Anomalous inflammatory responses triggered by the metabolic syndrome cause renal injury. This discovery links renal lipid accumulation with lipotoxicity to inflammation and may explain the insidious fibrosis and cellular decay characteristic of nephropathy in the metabolic syndrome. However, it is not clear whether control of inflammation protects the kidney independently of lipid accumulation, which is a required step for lipotoxicity in hyperglycemia and dyslipidemia. We hypothesized that in rats with the metabolic syndrome, and overt nephropathy, treatment with mycophenolate mofetil (MMF; 10 mg·kg-1 ·day-1 ip for 14 wk) would reduce the abnormal renal lipid depots and limit renal inflammation and injury. We studied groups of lean and obese F1 hybrid Zucker fatty diabetic/spontaneous hypertensive heart failure (ZS) rats. MMF did not affect lean rats. In obese ZS rats, MMF did not change severe hyperglycemia or the higher kidney loads of unutilized lipid and peroxidation products. Nonetheless, MMF dramatically reduced diabetes/obesity-derived systemic and renal inflammation, limited renal size, hyperfiltration, and fibrosis. These data indicate that in rats, anti-inflammatory therapy presumably acting downstream, and independently of lipotoxicity, can effectively limit renal injury and fibrosis.

Original languageEnglish
JournalAmerican Journal of Physiology - Renal Physiology
Volume293
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Phenotype
Kidney
Inflammation
Fibrosis
Lipids
Hyperglycemia
Wounds and Injuries
Mycophenolic Acid
Dyslipidemias
Lipid Peroxidation
Anti-Inflammatory Agents
Heart Failure
Obesity
Therapeutics

Keywords

  • Diabetic nephropathies
  • Lipid peroxidation

ASJC Scopus subject areas

  • Physiology

Cite this

Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy. / Dominguez, Jesus; Wu, Pengfei; Packer, C. Subah; Temm, Constance; Kelly, Katherine.

In: American Journal of Physiology - Renal Physiology, Vol. 293, No. 3, 09.2007.

Research output: Contribution to journalArticle

@article{83c8c43eb96c4b558cdba6aaa09e6d55,
title = "Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy",
abstract = "Anomalous inflammatory responses triggered by the metabolic syndrome cause renal injury. This discovery links renal lipid accumulation with lipotoxicity to inflammation and may explain the insidious fibrosis and cellular decay characteristic of nephropathy in the metabolic syndrome. However, it is not clear whether control of inflammation protects the kidney independently of lipid accumulation, which is a required step for lipotoxicity in hyperglycemia and dyslipidemia. We hypothesized that in rats with the metabolic syndrome, and overt nephropathy, treatment with mycophenolate mofetil (MMF; 10 mg·kg-1 ·day-1 ip for 14 wk) would reduce the abnormal renal lipid depots and limit renal inflammation and injury. We studied groups of lean and obese F1 hybrid Zucker fatty diabetic/spontaneous hypertensive heart failure (ZS) rats. MMF did not affect lean rats. In obese ZS rats, MMF did not change severe hyperglycemia or the higher kidney loads of unutilized lipid and peroxidation products. Nonetheless, MMF dramatically reduced diabetes/obesity-derived systemic and renal inflammation, limited renal size, hyperfiltration, and fibrosis. These data indicate that in rats, anti-inflammatory therapy presumably acting downstream, and independently of lipotoxicity, can effectively limit renal injury and fibrosis.",
keywords = "Diabetic nephropathies, Lipid peroxidation",
author = "Jesus Dominguez and Pengfei Wu and Packer, {C. Subah} and Constance Temm and Katherine Kelly",
year = "2007",
month = "9",
doi = "10.1152/ajprenal.00021.2007",
language = "English",
volume = "293",
journal = "American Journal of Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy

AU - Dominguez, Jesus

AU - Wu, Pengfei

AU - Packer, C. Subah

AU - Temm, Constance

AU - Kelly, Katherine

PY - 2007/9

Y1 - 2007/9

N2 - Anomalous inflammatory responses triggered by the metabolic syndrome cause renal injury. This discovery links renal lipid accumulation with lipotoxicity to inflammation and may explain the insidious fibrosis and cellular decay characteristic of nephropathy in the metabolic syndrome. However, it is not clear whether control of inflammation protects the kidney independently of lipid accumulation, which is a required step for lipotoxicity in hyperglycemia and dyslipidemia. We hypothesized that in rats with the metabolic syndrome, and overt nephropathy, treatment with mycophenolate mofetil (MMF; 10 mg·kg-1 ·day-1 ip for 14 wk) would reduce the abnormal renal lipid depots and limit renal inflammation and injury. We studied groups of lean and obese F1 hybrid Zucker fatty diabetic/spontaneous hypertensive heart failure (ZS) rats. MMF did not affect lean rats. In obese ZS rats, MMF did not change severe hyperglycemia or the higher kidney loads of unutilized lipid and peroxidation products. Nonetheless, MMF dramatically reduced diabetes/obesity-derived systemic and renal inflammation, limited renal size, hyperfiltration, and fibrosis. These data indicate that in rats, anti-inflammatory therapy presumably acting downstream, and independently of lipotoxicity, can effectively limit renal injury and fibrosis.

AB - Anomalous inflammatory responses triggered by the metabolic syndrome cause renal injury. This discovery links renal lipid accumulation with lipotoxicity to inflammation and may explain the insidious fibrosis and cellular decay characteristic of nephropathy in the metabolic syndrome. However, it is not clear whether control of inflammation protects the kidney independently of lipid accumulation, which is a required step for lipotoxicity in hyperglycemia and dyslipidemia. We hypothesized that in rats with the metabolic syndrome, and overt nephropathy, treatment with mycophenolate mofetil (MMF; 10 mg·kg-1 ·day-1 ip for 14 wk) would reduce the abnormal renal lipid depots and limit renal inflammation and injury. We studied groups of lean and obese F1 hybrid Zucker fatty diabetic/spontaneous hypertensive heart failure (ZS) rats. MMF did not affect lean rats. In obese ZS rats, MMF did not change severe hyperglycemia or the higher kidney loads of unutilized lipid and peroxidation products. Nonetheless, MMF dramatically reduced diabetes/obesity-derived systemic and renal inflammation, limited renal size, hyperfiltration, and fibrosis. These data indicate that in rats, anti-inflammatory therapy presumably acting downstream, and independently of lipotoxicity, can effectively limit renal injury and fibrosis.

KW - Diabetic nephropathies

KW - Lipid peroxidation

UR - http://www.scopus.com/inward/record.url?scp=34548645095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548645095&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00021.2007

DO - 10.1152/ajprenal.00021.2007

M3 - Article

C2 - 17596532

AN - SCOPUS:34548645095

VL - 293

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1857

IS - 3

ER -